A single-arm, investigator-initiated study of the efficacy, safety, and tolerability of intravitreal aflibercept injection in subjects with exudative age-related macular degeneration previously treated with ranibizumab or bevacizumab (ASSESS study): 12-month analysis [Corrigendum]

Singh RP, Srivastava SK, Ehlers JP, et al. Clin Ophthalmol. 2015;9:1759–1766.On page 1763, Figure 4 has been amended. Read the original article

Bibliographic Details
Main Authors: Singh RP, Srivastava SK, Ehlers JP, Silva FQ, Bedi R, Schachat AP, Kaiser PK
Format: Article
Language:English
Published: Dove Medical Press 2017-02-01
Series:Clinical Ophthalmology
Online Access:https://www.dovepress.com/httpswwwdovepresscomcorrigendum-a-single-arm-investigator--peer-reviewed-article-OPTH
id doaj-239904354ae741d0b8a664e266ab236e
record_format Article
spelling doaj-239904354ae741d0b8a664e266ab236e2020-11-24T21:11:20ZengDove Medical PressClinical Ophthalmology1177-54832017-02-01Volume 1130330431164A single-arm, investigator-initiated study of the efficacy, safety, and tolerability of intravitreal aflibercept injection in subjects with exudative age-related macular degeneration previously treated with ranibizumab or bevacizumab (ASSESS study): 12-month analysis [Corrigendum]Singh RPSrivastava SKEhlers JPSilva FQBedi RSchachat APKaiser PKSingh RP, Srivastava SK, Ehlers JP, et al. Clin Ophthalmol. 2015;9:1759–1766.On page 1763, Figure 4 has been amended. Read the original articlehttps://www.dovepress.com/httpswwwdovepresscomcorrigendum-a-single-arm-investigator--peer-reviewed-article-OPTH
collection DOAJ
language English
format Article
sources DOAJ
author Singh RP
Srivastava SK
Ehlers JP
Silva FQ
Bedi R
Schachat AP
Kaiser PK
spellingShingle Singh RP
Srivastava SK
Ehlers JP
Silva FQ
Bedi R
Schachat AP
Kaiser PK
A single-arm, investigator-initiated study of the efficacy, safety, and tolerability of intravitreal aflibercept injection in subjects with exudative age-related macular degeneration previously treated with ranibizumab or bevacizumab (ASSESS study): 12-month analysis [Corrigendum]
Clinical Ophthalmology
author_facet Singh RP
Srivastava SK
Ehlers JP
Silva FQ
Bedi R
Schachat AP
Kaiser PK
author_sort Singh RP
title A single-arm, investigator-initiated study of the efficacy, safety, and tolerability of intravitreal aflibercept injection in subjects with exudative age-related macular degeneration previously treated with ranibizumab or bevacizumab (ASSESS study): 12-month analysis [Corrigendum]
title_short A single-arm, investigator-initiated study of the efficacy, safety, and tolerability of intravitreal aflibercept injection in subjects with exudative age-related macular degeneration previously treated with ranibizumab or bevacizumab (ASSESS study): 12-month analysis [Corrigendum]
title_full A single-arm, investigator-initiated study of the efficacy, safety, and tolerability of intravitreal aflibercept injection in subjects with exudative age-related macular degeneration previously treated with ranibizumab or bevacizumab (ASSESS study): 12-month analysis [Corrigendum]
title_fullStr A single-arm, investigator-initiated study of the efficacy, safety, and tolerability of intravitreal aflibercept injection in subjects with exudative age-related macular degeneration previously treated with ranibizumab or bevacizumab (ASSESS study): 12-month analysis [Corrigendum]
title_full_unstemmed A single-arm, investigator-initiated study of the efficacy, safety, and tolerability of intravitreal aflibercept injection in subjects with exudative age-related macular degeneration previously treated with ranibizumab or bevacizumab (ASSESS study): 12-month analysis [Corrigendum]
title_sort single-arm, investigator-initiated study of the efficacy, safety, and tolerability of intravitreal aflibercept injection in subjects with exudative age-related macular degeneration previously treated with ranibizumab or bevacizumab (assess study): 12-month analysis [corrigendum]
publisher Dove Medical Press
series Clinical Ophthalmology
issn 1177-5483
publishDate 2017-02-01
description Singh RP, Srivastava SK, Ehlers JP, et al. Clin Ophthalmol. 2015;9:1759–1766.On page 1763, Figure 4 has been amended. Read the original article
url https://www.dovepress.com/httpswwwdovepresscomcorrigendum-a-single-arm-investigator--peer-reviewed-article-OPTH
work_keys_str_mv AT singhrp asinglearminvestigatorinitiatedstudyoftheefficacysafetyandtolerabilityofintravitrealafliberceptinjectioninsubjectswithexudativeagerelatedmaculardegenerationpreviouslytreatedwithranibizumaborbevacizumabassessstudy12monthanalysiscorrigendum
AT srivastavask asinglearminvestigatorinitiatedstudyoftheefficacysafetyandtolerabilityofintravitrealafliberceptinjectioninsubjectswithexudativeagerelatedmaculardegenerationpreviouslytreatedwithranibizumaborbevacizumabassessstudy12monthanalysiscorrigendum
AT ehlersjp asinglearminvestigatorinitiatedstudyoftheefficacysafetyandtolerabilityofintravitrealafliberceptinjectioninsubjectswithexudativeagerelatedmaculardegenerationpreviouslytreatedwithranibizumaborbevacizumabassessstudy12monthanalysiscorrigendum
AT silvafq asinglearminvestigatorinitiatedstudyoftheefficacysafetyandtolerabilityofintravitrealafliberceptinjectioninsubjectswithexudativeagerelatedmaculardegenerationpreviouslytreatedwithranibizumaborbevacizumabassessstudy12monthanalysiscorrigendum
AT bedir asinglearminvestigatorinitiatedstudyoftheefficacysafetyandtolerabilityofintravitrealafliberceptinjectioninsubjectswithexudativeagerelatedmaculardegenerationpreviouslytreatedwithranibizumaborbevacizumabassessstudy12monthanalysiscorrigendum
AT schachatap asinglearminvestigatorinitiatedstudyoftheefficacysafetyandtolerabilityofintravitrealafliberceptinjectioninsubjectswithexudativeagerelatedmaculardegenerationpreviouslytreatedwithranibizumaborbevacizumabassessstudy12monthanalysiscorrigendum
AT kaiserpk asinglearminvestigatorinitiatedstudyoftheefficacysafetyandtolerabilityofintravitrealafliberceptinjectioninsubjectswithexudativeagerelatedmaculardegenerationpreviouslytreatedwithranibizumaborbevacizumabassessstudy12monthanalysiscorrigendum
AT singhrp singlearminvestigatorinitiatedstudyoftheefficacysafetyandtolerabilityofintravitrealafliberceptinjectioninsubjectswithexudativeagerelatedmaculardegenerationpreviouslytreatedwithranibizumaborbevacizumabassessstudy12monthanalysiscorrigendum
AT srivastavask singlearminvestigatorinitiatedstudyoftheefficacysafetyandtolerabilityofintravitrealafliberceptinjectioninsubjectswithexudativeagerelatedmaculardegenerationpreviouslytreatedwithranibizumaborbevacizumabassessstudy12monthanalysiscorrigendum
AT ehlersjp singlearminvestigatorinitiatedstudyoftheefficacysafetyandtolerabilityofintravitrealafliberceptinjectioninsubjectswithexudativeagerelatedmaculardegenerationpreviouslytreatedwithranibizumaborbevacizumabassessstudy12monthanalysiscorrigendum
AT silvafq singlearminvestigatorinitiatedstudyoftheefficacysafetyandtolerabilityofintravitrealafliberceptinjectioninsubjectswithexudativeagerelatedmaculardegenerationpreviouslytreatedwithranibizumaborbevacizumabassessstudy12monthanalysiscorrigendum
AT bedir singlearminvestigatorinitiatedstudyoftheefficacysafetyandtolerabilityofintravitrealafliberceptinjectioninsubjectswithexudativeagerelatedmaculardegenerationpreviouslytreatedwithranibizumaborbevacizumabassessstudy12monthanalysiscorrigendum
AT schachatap singlearminvestigatorinitiatedstudyoftheefficacysafetyandtolerabilityofintravitrealafliberceptinjectioninsubjectswithexudativeagerelatedmaculardegenerationpreviouslytreatedwithranibizumaborbevacizumabassessstudy12monthanalysiscorrigendum
AT kaiserpk singlearminvestigatorinitiatedstudyoftheefficacysafetyandtolerabilityofintravitrealafliberceptinjectioninsubjectswithexudativeagerelatedmaculardegenerationpreviouslytreatedwithranibizumaborbevacizumabassessstudy12monthanalysiscorrigendum
_version_ 1716753746488197120